Pharmacokinetics of cefotaxime in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis. 1984

H Hasegawa, and A Imada, and A Horiuchi, and Y Nishii, and M Fukushima, and E Kurokawa

The pharmacokinetics of cefotaxime were studied in 13 patients on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD). One gram of cefotaxime was administered intravenously or intraperitoneally. In the haemodialysis patients, the serum concentration after 4h was 9.4 mg/l and the T1/2 was 1.31 h. The 6-h value and T1/2 in the CAPD (intravenous) patients were 4.5 mg/l and 1.59 hours, while the peak value in the dialysate was 11.6 mg/l. In the CAPD (intraperitoneal) patients, the cefotaxime concentration in the dialysate was 157 mg/l after 6 h and the peak value in the serum was 9.1 mg/l. Since cefotaxime is easily removed from the blood by both the haemodialysis and CAPD methods, accumulation of the drug in patients undergoing dialysis is unlikely to occur.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010530 Peritoneal Dialysis Dialysis fluid being introduced into and removed from the peritoneal cavity as either a continuous or an intermittent procedure. Dialyses, Peritoneal,Dialysis, Peritoneal,Peritoneal Dialyses
D010531 Peritoneal Dialysis, Continuous Ambulatory Portable peritoneal dialysis using the continuous (24 hours a day, 7 days a week) presence of peritoneal dialysis solution in the peritoneal cavity except for periods of drainage and instillation of fresh solution. CAPD,Continuous Ambulatory Peritoneal Dialysis
D010538 Peritonitis INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs. Primary Peritonitis,Secondary Peritonitis,Peritonitis, Primary,Peritonitis, Secondary
D002439 Cefotaxime Semisynthetic broad-spectrum cephalosporin. Benaxima,Biosint,Cefotaxim,Cefotaxime Sodium,Cefradil,Cephotaxim,Claforan,Fotexina,HR-756,Kendrick,Klaforan,Primafen,Ru-24756,Taporin,HR 756,HR756,Ru 24756,Ru24756,Sodium, Cefotaxime
D005260 Female Females
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

H Hasegawa, and A Imada, and A Horiuchi, and Y Nishii, and M Fukushima, and E Kurokawa
January 1990, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis,
H Hasegawa, and A Imada, and A Horiuchi, and Y Nishii, and M Fukushima, and E Kurokawa
July 1992, Antimicrobial agents and chemotherapy,
H Hasegawa, and A Imada, and A Horiuchi, and Y Nishii, and M Fukushima, and E Kurokawa
January 2003, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis,
H Hasegawa, and A Imada, and A Horiuchi, and Y Nishii, and M Fukushima, and E Kurokawa
April 1981, Antimicrobial agents and chemotherapy,
H Hasegawa, and A Imada, and A Horiuchi, and Y Nishii, and M Fukushima, and E Kurokawa
May 1984, Antimicrobial agents and chemotherapy,
H Hasegawa, and A Imada, and A Horiuchi, and Y Nishii, and M Fukushima, and E Kurokawa
March 1984, Antimicrobial agents and chemotherapy,
H Hasegawa, and A Imada, and A Horiuchi, and Y Nishii, and M Fukushima, and E Kurokawa
August 1983, Antimicrobial agents and chemotherapy,
H Hasegawa, and A Imada, and A Horiuchi, and Y Nishii, and M Fukushima, and E Kurokawa
June 1990, Clinical pharmacokinetics,
H Hasegawa, and A Imada, and A Horiuchi, and Y Nishii, and M Fukushima, and E Kurokawa
January 2009, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis,
H Hasegawa, and A Imada, and A Horiuchi, and Y Nishii, and M Fukushima, and E Kurokawa
May 1988, Journal of clinical pharmacology,
Copied contents to your clipboard!